Accepted Manuscript

2017 international meeting of the Global Virus Network

Mike Catton, Glenda Gray, Diane Griffin, Hideki Hasegawa, Stephen Kent, Jason
Mackenzie, Edward McSweegan, Natalia Mercer, Linfa Wang

PII: S0166-3542(18)30049-4
DOI: 10.1016/j.antiviral.2018.02.001
Reference: AVR 4240

To appear in: Antiviral Research

Received Date: 24 January 2018

Accepted Date: 1 February 2018

Please cite this article as: Catton, M., Gray, G., Griffin, D., Hasegawa, H., Kent, S., Mackenzie, J.,
McSweegan, E., Mercer, N., Wang, L., 2017 international meeting of the Global Virus Network, Antiviral
Research (2018), doi: 10.1016/j.antiviral.2018.02.001.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
 ACCEPTED MANUSCRIPT

2017 International Meeting of the Global Virus Network

Mike Cattona, Glenda Grayb, Diane Griffinc, Hideki Hasegawad, Stephen Kente, Jason

Mackenziee, Edward McSweeganf,*, Natalia Mercerf, Linfa Wangg.

a
Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute for Infection and
Immunity, Melbourne, Australia
b
South African Medical Research Council, Cape Town, South Africa
c
Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore,
MD, USA
d
National Institute of Infectious Diseases, Tokyo, Japan
e
Department of Microbiology and Immunology, Peter Doherty Institute for Infection and
Immunity, Melbourne, Australia
f
Global Virus Network, Baltimore, MD, USA
g
Emerging Infectious Diseases Programme, Duke-NUS Medical School, Singapore

Keywords:

Global Virus Network, Emerging viruses, International collaborations, Medical virology

* Corresponding author. Global Virus Network, 725 W. Lombard St., Rm. S-420,
Baltimore, MD 21201, USA.
E-mail address: [email protected] (E. McSweegan).
Abstract

The Global Virus Network (GVN) was established in 2011 to strengthen research and responses

to emerging viral causes of human disease and to prepare against new viral pandemics. There are

now 40 GVN Centers of Excellence and 6 Affiliate laboratories in 24 countries. The 2017

meeting was held from September 25-27 in Melbourne, Australia, and was hosted by the Peter

Doherty Institute for Infection and Immunity and the Institut Pasteur. This report highlights the

recent accomplishments of GVN researchers in several important areas of medical virology,

including the recent Zika epidemic, infections by human papillomavirus, influenza, HIV,

hepatitis C, HTLV-1, and chikungunya viruses, and new and emerging viruses in the Australasia

region. Plans for the 2018 meeting also are noted.

1. Introduction

The Global Virus Network (GVN) was established in 2011 to strengthen research in

response to human viral diseases and to prepare for new viral pandemic threats (Mann, 2011).

The GVN now has 40 Centers of Excellence and 6 Affiliate laboratories in 24 countries (Figure

1). Network scientists meet annually to address research and collaborative priorities, learn about

each member's current work and plan future programs. These international conferences have

become critical platforms for the exchange of ideas.

The 2017 international GVN meeting was held from September 25-27 in Melbourne,

Australia, in partnership with the Peter Doherty Institute for Infection and Immunity, and the

Institut Pasteur. It brought together directors of GVN Centers and their colleagues for three days

of scientific presentations and discussions of emerging and re-emerging viral threats. The

Melbourne meeting was the first GVN event open to non-GVN scientists and students.

Investigators, clinicians and students from area institutes and universities had the opportunity to

attend scientific sessions and present ongoing student work at a poster session to expand

opportunities for collaborative dialogue, particularly with young virologists. The main objectives

of the meeting were to present and discuss current findings in medical virology, including

advances in research on HIV vaccines; HTLV-1 infections among indigenous Australians; other

important Australasian viruses; and address the GVN's annual strategy for continued

development.

2. The Global Virus Network

The formation of the GVN and the rationale for its structure have been previously

described (Akkina et al., 2017 ). Currently, the GVN consists of 40 Centers of Excellence and 6

Affiliate laboratories in 24 countries. GVN’s mission is focused on strengthening medical

research and responses to viral causes of human disease, and to preparing for new viral

threats. That mission is achieved through basic research, public education, and advocacy.

3. The 2017 Robert C. Gallo Award

Diane Griffin, PhD, MD, University Distinguished Service Professor, and Alfred and Jill

Sommer Chair of the W. Harry Feinstone Department of Molecular Microbiology and

Immunology at the Johns Hopkins Bloomberg School of Public Health—a GVN Center of

Excellence—was presented with the Robert C. Gallo Award for Scientific Excellence and

Leadership for her studies on measles and alphavirus encephalomyelitis, which have delineated

the role of host immune responses in virus clearance, vaccine-induced protection from infection,

tissue damage and immune suppression. Dr. Griffin also was cited for her leadership role within

the GVN’s international conferences and virology training programs, for making important basic

science contributions to medical virology.

The award is named for Robert C. Gallo, MD, co-founder and director, The Homer &

Martha Gudelsky Distinguished Professor in Medicine, Institute of Human Virology, University

of Maryland School of Medicine, and Co-Founder and Scientific Director of the GVN. Dr. Gallo

and his co-workers discovered interleukin-2 (IL-2), followed by the discovery of the first human

retroviruses, Human T-Cell Leukemia Virus-1 (HTLV-1) and HTLV-2. He and his colleagues

co-discovered HIV as the cause of AIDS and developed the first HIV blood test.

4. Pre-Meeting and Public Forum on HTLV-1 in remote indigenous Australians

While not part of the formal GVN meeting, there was a morning session on HTLV-1

infection chaired by Damian Purcell of the Peter Doherty Institute and a closing summary by
Robert Gallo. Some of what was discussed has been published (Tagaya and Gallo, 2017; Gallo et

al., 2017), and it is anticipated that additional publications by other speakers will be forthcoming.

5. Scientific presentations

5.1 Re-awaking to HTLV-1 in indigenous communities

Antoine Gessain (Institut Pasteur, Paris) reviewed the epidemiology, origin and genetic

diversity of HTLV-1. In 2012, the EU Commission requested the European Centre for Disease

Prevention and Control (ECDC) to construct a map indicating all the HTLV-1 high-prevalence

areas in the world. By analyzing more than 1000 papers and hundreds of abstracts, Gessain and

colleagues provided the first complete epidemiological data (maps and tables) for the 203

world’s countries (ECDC, 2015). In most of the highly endemic areas, HTLV-1 is mainly

disseminated and maintained in the human population through intra-familial transmission

(mother-to-child and by sexual intercourse). More rarely, transmission may also occur by

transfusion or intravenous drug use. HTLV-1 originated from a simian retrovirus called simian

T-leukemia virus type 1 (STLV-1), which is widespread in Old World monkey and ape species.

The idea that HTLV-1 originated from STLV-1 is mainly based on the very high sequence

homology (African subtypes b, d, e, f) found between some STLV-1 strains and HTLV-1 found

in individuals, including hunters, living in Central/West Africa. However, data concerning

transmission of STLV-1 to humans in natura and modes of acquisition remain quite scarce.

Gessain also reviewed reported cases of HTLV-3 and -4, and speculated on the future emergence

of these viruses and Simian Foamy viruses (Gessain et al., 2013).

Lloyd Einsiedel (Baker Heart and Diabetes Institute, Australia) reported on HTLV-1

subtype C as a major cause of morbidity and mortality among indigenous Australians. The virus
is highly endemic to central Australia where more than half of all indigenous adults residing in

some remote communities are infected. Infection is associated with a rapidly progressive

haematological malignancy (adult T-cell leukemia, ATL), inflammatory diseases involving

various organ systems and an increased likelihood and severity of other infections, notably with

Strongyloides stercoralis. In central Australia, each of the major HTLV-1-associated diseases

has been described; however, in this setting HTLV-1 infection is most often associated with

chronic respiratory disease, including life-threatening, severe bronchiectasis, and with invasive

bacterial infections (Einsiedel et al., 2012). The region has the highest reported prevalence of

adult bronchiectasis, and among the highest bloodstream infection incidence rates, worldwide.

The risk of bronchiectasis and the extent of pulmonary injury are strongly associated with the

HTLV-1 proviral load (pVL), which also predicts risk of invasive bacterial infection. The

association between HTLV-1 pVL and these life-threatening conditions is consistent with recent

findings that higher HTLV-1 pVL are associated with an increased risk of death in a large

prospective cohort of Indigenous adults (Einsiedel et al., 2016). High rates of HTLV-1 infection

and HTLV-1-associated diseases contribute substantially to the burden of ill health and early

mortality among indigenous people in central Australia.

Charles R. M. Bangham (Imperial College, U.K.) noted that HTLV-1 causes disabling

chronic inflammatory diseases or an aggressive, rapidly fatal malignancy, adult T-cell

leukaemia/lymphoma, in about 10% of infected people. In addition, HTLV-1 predisposes to and

exacerbates infections with Mycobacterium tuberculosis, Strongyloides stercoralis and

Staphylococcus aureus, with severe and sometimes fatal consequences. It has recently been

shown that HTLV-1 also causes and exacerbates bronchiectasis, bronchitis and bronchiolitis. The

risk of these HTLV-1-associated diseases is strongly correlated with the proviral load, which
frequently exceeds 10% of peripheral blood mononuclear cells (PBMCs). The virus, which is

non-cytolytic, drives proliferation of the infected CD4+ T cell, and the high proviral load is

limited by a strong, chronically activated cytotoxic T lymphocyte (CTL) response to HTLV-1.

Until recently, it was believed that HTLV-1 persisted in vivo chiefly by continuous oligoclonal

proliferation of about 100 clones of HTLV-1-infected CD4+ T cells. However, Bangham and

colleagues have shown that a typical individual carries between 10 4 and 105 clones, and the

proviral load – the chief correlate of disease – is determined by the number of clones, not by

oligoclonal proliferation. It was also believed that HTLV-1 was latent in vivo, but the existence

of the persistently activated CTL response in virtually all hosts strongly argues that the virus is

not latent but is frequently expressed. This suggests that the virus undergoes intermittent bursts

of expression in vivo.

Bangham presented data from single-molecule RNA fluorescence in situ hybridization

(smFISH) that the provirus indeed undergoes intermittent, intense bursts of expression. Work is

under way to identify the factors that regulate the frequency, size and duration of these bursts. In

addition, spontaneous reactivation of HTLV-1 from latency in fresh PBMCs is governed by the

molecular oxygen availability and by glycolysis. Finally, he and colleagues discovered that

HTLV-1 alters host chromatin structure in the infected cell, by binding the chromatin

architectural protein CTCF, which regulates higher-order chromatin structure and gene

expression in vertebrates. This observation implies that HTLV-1 does a remarkable experiment

of nature, by changing the conformation of chromatin in tens of thousands of different ways in

each infected host (Satou, et al., 2016). Studies are under way to test the hypotheses that CTCF

regulates HTLV-1 latency, and that the abnormal chromatin looping caused by CTCF can

deregulate host gene expression and so may act as an oncogenic driver.

 Fabiola Martin (University of Queensland, Australia; University of York, U.K.)

discussed the clinical diagnosis and treatment of HTLV-1 diseases. The discovery of a cure for

HTLV-1, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-

cell leukaemia/lymphoma (ATLL) has been an ongoing process of refinement since the early

1980s. Martin presented summaries of more than 35 years of published and empirical

intervention options, including HTLV prevention strategies as part of the international HTLV

eradication efforts (Einsiedel et al., 2018).

Toshiki Watanabe (University of Tokyo, Japan) described recent government responses

to HTLV-1 infection in Japan. Since the first report of ATL by Takatsuki’s group in 1977,

Japanese clinicians and researchers have made major contributions to understanding the virology

of HTLV-1 and the pathophysiology of ATL, as well as identifying other HTLV-1-associated

diseases such as HAM/TSP and HTLV-1 uveitis (HU). In the first decade of 2000, groups of

Japanese patients with HTLV-1-associated diseases petitioned the government for improved

health care and treatment, as well as continuous and strong support for clinical and basic

research. In 2010, the government organized a HTLV-1 Task Force composed of the Prime

Minister and government officials, representatives of patient groups, and medical specialists.

Subsequently, a nationwide campaign began in 2011 with screening for HTLV-1 antibody in all

pregnant women to prevent new mother-to-child transmissions. Counseling also was initiated for

HTLV-1 carriers and HAM/ATL patients. Some of the results of stepped-up government support

for HTLV-1 research and care have been reported (Satake et al., 2016; Nosaka et al., 2017).

5.2 New and emerging viruses in Australasia and beyond

 Linfa Wang (Duke-NUS Medical School, Singapore) presented a review of his 20 years

of research on the importance of bats as natural reservoir of viruses. Specifically, he addressed

three questions:

1. Are bats true reservoirs of emerging viruses? Since the discovery of rabies virus in bats

more than 100 years ago, bats have been known to carry zoonotic viruses. But the field

remained relatively “quiet” until the discovery of Hendra virus in Australian bats, which was

responsible for lethal outbreaks in horses and humans. Since then, bats have been confirmed or

suspected as reservoirs of several emerging viruses, including Nipah, SARS, MERS, Ebola and

Marburg viruses. Although scientists working in this field still debate whether bats are the true

reservoir of Ebola virus, for example, Wang pointed out that it took an international

collaborative team more than ten years to obtain convincing evidence of the bat origin of the

SARS coronavirus (Ge et al., 2013).

2. Are bats special in their ability to host viruses? There are two working hypotheses

associated with this question. First, it is difficult to induce experimental infections in bats with

many viruses lethal to humans and livestock. Second, bats can harbor more viruses on a per

species basis and there is a greater genetic diversity of viruses in bats than in other mammals.

Evidence has been gathered to support these hypotheses, although most of them are based on

retrospective studies of past literature. The most significant study examined a database of 2,805

mammal-virus associations and concluded that bats harbor a significantly higher proportion of

zoonotic viruses than any other mammalian order (Olival et al., 2017).

3. What makes bats special? Wang noted that bats have a long lifespan and are less prone to

cancer. He hypothesized that the evolutionary adaptation to flight has resulted in a unique

immune system significantly different from terrestrial mammals. He presented genomic data
indicating a more robust positive selection of genes responsible for DNA damage pathways

(Zhang et al., 2013). The most recently data obtained from his group suggests that the overall

dampening of inflammatory responses may be key to why bats can carry so many viruses, yet

seldom develop symptomatic infections.

Alex Greenwood (Leibniz Institute for Zoo and Wildlife Research, Berlin, Germany)

introduced the concept of exogenous and endogenous retroviruses. While it is known that the

mammalian genome is composed of up to 11% endogenous retroviral elements (ERVs), most of

them completed their invasion millions of years ago obscuring the changes in virus and host

associated with them. The koala retrovirus (KoRV) is one of the few examples of a virus that is

currently in the earliest stages of transitioning from an exogenous retrovirus to an ERV

(Tarlinton et al., 2006). By going through a collection of archived samples of modern wild and

zoo koalas dating back to 1891, Greenwood and his collaborators found crucial early events in

endogenization involving recombination, often mediated by existing retroviral-like elements

already resident in the host genome. These recombination events disable the exogenous

retrovirus making it less potentially harmful to the host while at the same time, the ancient

retroviral-like elements may re-establish themselves as actively propagating retroelements

(Hobbs et al., 2017). In the context of trying to find the origin of KoRV, Greenwood, et al.

confirmed its close relationship to the gibbon ape leukemia virus (GALV). Both are likely from

recent interspecies transmissions.

Phylogenetically, two rodent viruses, Melomys bertoni retrovirus (MbRV) and Melomys

woolly monkey-like virus (MelWMV) are the closest to the KoRV/GALV-like viruses identified

to date (Alfano et al., 2016). Greenwood concluded that very close relatives of KoRV/GALV
have been circulating in a variety of mammalian taxa within the Australo-Papuan region east of

the Wallace Line.

Lorena Brown (University of Melbourne, Australia) presented a new concept in antiviral

drug design. While most current antiviral strategies tend to target specific viral proteins and

inhibit their function, Brown described antiviral drugs that are modular in structure, consisting of

a viral attachment domain and an effector domain. In general, the attachment domain can be

antibody or any domain or motif structure that binds the surface of a virus. An effector domain

can vary from an enzyme to a charge cloud.

In collaboration with Aus Bio Ltd., the concept was tested against influenza virus. Entry of

influenza virus into cells is by receptor-mediated endocytosis. As the environment of the

endosome becomes more acidic, the viral hemagglutinin (HA) undergoes a conformational

change to reveal a hydrophobic fusion region that penetrates the endosomal membrane, thus

initiating the life cycle of virus replication inside the cell. Candidate drug molecules use an

attachment domain that binds to HA, and an effector domain that provides a negatively-charged

environment to trigger a premature conformational change in the neighbouring HA to prevent

viral replication. Brown presented in vivo data on two drugs, MD185 and MD345, that provided

better protection in mouse and ferret models than did zanamivir. These constructs appear to

provide an extended therapeutic window until the adaptive immune system comes into play. The

long-duration activity of the drugs suggests they may be useful in prophylaxis, especially in a

pandemic context.

Soren Alexandersen, (Geelong Centre for Emerging Infectious Diseases, Australia),

described outbreaks of severe infections among Australian infants caused by a recombinant

strain of human parechovirus type 3. Human parechovirus types 1-16 (HPeV1-16) are positive-
strand RNA viruses. Type 3 parechovirus (HPeV3) causes a severe disease in infants with

mortality up to 6% and potential long-term sequelae. As this was a newly recognised disease of

infants, there was no diagnostic test available in Australia until 2013.

During the investigation of a 2015 HPeV3 outbreak, it was found that the genome of the

Australian viruses had undergone a major recombination event that took place between March

2012 and November 2013, followed by further virus evolution and possibly recombination. The

phylogenetic and network analyses from the Geelong group support a temporal evolution from

the first Australian recombinant virus sequence from November 2013 to March/April 2014 to the

2015 outbreak. Their data showed that the 2015 outbreak viruses are recombined from the

Yamagata 2011 lineage and an as yet unknown virus (Nelson et al., 2017).

This unknown virus, the donor of the non-structural coding region, may come from a not-yet

sequenced human parechovirus or alternatively, from a potential unknown animal source, as

similar viruses do infect animals such as the recombinant HPeV4 detected in pigs in South

America (Nix et al., 2013). Finally, Alexandersen observed that the HPeV3 outbreaks seem to

follow a 2-3-year cycle, suggesting there may be another wave of HPeV3 outbreaks in Australia

in 2017/8.

5.3 Pandemic and epidemic viruses

Nobel Laureate Peter Doherty, (Peter Doherty Institute for Infection and Immunity,

Australia), provided a review of CD8 + cytotoxic T lymphocyte contributions to antiviral

immunity. The human family is constantly challenged by viruses, with epidemic/ pandemic

pathogens either emerging from wildlife or domestic animal reservoirs, or as a consequence of

“immune escape” mutations in strains that are circulating in us. Vaccines that promote long-term
antibody-mediated immunity to “mop up” invaders can provide immediate protection though, of

course, as Doherty noted, we have no such products when something new and unexpected hits.

As our most intimate parasites, viruses grow only within living cells. As a consequence, part of

the process of recovery requires the elimination of these cellular “factories” of pathogen

production. The “hit man” of immunity that does this job is a circulating white blood cell, the

virus-specific, CD8+ “killer” T-cell, or cytotoxic T-lymphocyte (CTL) and the CTL is targeted

to cell surfaces via recognition of viral peptide bound to self MHC class I glycoproteins. Some

recent findings concerning HLA type and influenza prevention and susceptibility are of

particular interest, especially with regard to the greater susceptibility of indigenous populations

to influenza.

Maël Bessaud (Institut Pasteur, Paris), reviewed genetic recombination among positive-

strand RNA viruses and suggested enteroviruses as a convenient model for in vitro studies of

recombination. In particular, mostly non-homologous recombinant genomes were seen; that is,

genomes with deletions or duplications, which can subsequently evolve into homologous

recombinant genomes. Regions where recombination occurs more frequently have been

identified. These hotspots bound genomic domains that can be considered as modules used to

engender new mosaic genomes through recombination. These results illustrate how

recombination is able to generate a wide genetic and phenotypic diversity and can promote the

emergence of new viruses.

Joaquim Segales (Centre de Recerca en Sanitat Animal, Spain) described dromedary

camels as models for Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) infection.

Experimental intranasal inoculations with MERS-CoV produces only upper respiratory tract

infection (URT) and mild clinical signs. Infectious virus is only detected in the trachea, large
bronchi and tracheobronchial lymph nodes, while viral RNA is more widely detectable in the

nose, the upper and lower respiratory tracts and in extrapulmonary lymphoid and visceral tissue.

Nasal, tracheal and bronchial inflammation are present, without gross lesions. A similar clinical-

pathological picture is seen after intranasal MERS-CoV inoculation of domestic new world

camelids, producing either no clinical signs (alpacas) or mild mucus secretion (llamas), with

MERS-CoV detectable in the URT (nasal swabs and trachea) of both species, and cleared from

the URT 7-10 days post-infection, concomitant with antibody responses. Pigs also may be

experimentally infected and show the presence of viral RNA in nasal swabs, trachea and bronchi

until 7-10 days postinoculation. Only very limited transmission to direct contact mates is seen

under experimental conditions. Experiments performed to date suggest that other large animal

domestic species such as horse, sheep and goat are not susceptible to MERS-CoV infection.

Ramesh Akkina (Colorado State University, USA) described new and improved

humanized mouse (hu-mouse) models that harbor a transplanted human immune system to study

viral pathogenesis, evolution, latency, and human immune responses to HIV, dengue and Zika

viruses (Schmitt et al., 2017). He outlined the use of Hu-mice as an alternative to in vitro viral

outgrowth assays (qVOA), which are currently the gold standard for measuring latent HIV in

cure research, but often fail to detect very low levels of replication-competent virus as evidenced

by the “Boston patients (Hayden, 2013).” Akkina showed that Hu-mice also provide a potential

animal model to study HIV-2, and for testing a three-drug formulation of anti-retrovirals (Hu et

al., 2017). Hu-mice are susceptible to HIV-2 infection and show persistent viremia and CD4 T-

cell loss, key hallmarks of AIDS pathogenesis.

Akkina also described how ideal animal models of human cell infections and human

immune responses are lacking for the flaviviruses, dengue and Zika. In dengue pathogenesis
studies, hu-mice were shown to be permissive for productive infection resulting in viremia

lasting up to three weeks. Fever—characteristic of dengue—was noted with infected mice

developing human neutralizing anti-dengue IgM and IgG antibodies. Recent experiments showed

that hu-mice (BLT mice) are also susceptible to Zika virus with chronic viremia lasting more

than 220 days. Virus-infected human monocytes/macrophages, B cells and hematopoietic stem

cells were found in bone marrow (Schmitt et al., 2018) Human neutralizing antibodies are

detected highlighting the use of this model for future vaccine testing.

5.4 Approaches to eliminating persistent viruses, Part 1

Peter Revill (The Doherty Institute in Melbourne) described the International Coalition

to Eliminate Hepatitis B Virus (ICE-HBV), which was established in 2016 to accelerate research

on cures for hepatitis B infection. The vision of ICE-HBV is to develop an international,

independent, research-based and patient-centered forum to coordinate, promote and foster

collaborative partnerships working towards a cure for chronic hepatitis B (CHB). Over 250

million people worldwide are chronically infected with HBV, and even though a prophylactic

vaccine and effective antiviral therapies are available, no post-infection cure exists. This is of

concern in the Asia-Pacific region, where over 118 million people, including 239,000

Australians live with CHB.

Recent advances in the field, such as the identification of the NTCP receptor for viral entry and

improved cell culture and animal models, are facilitating a new era in cure research worldwide

(Watashi et. al., 2014; Revill et. al., 2016). Through its global network, ICE-HBV is working to

promote research collaborations aimed at developing a cure as quickly as possible.

 Liz Bannister (Royal Melbourne Hospital, Australia) noted that children in the world’s

poorest countries often are not vaccinated against HBV, including much of Africa, where 75

million people are chronically infected. With immigration of peoples from highly endemic

regions, including sub-Saharan Africa, Australia’s HBV prevalence continues to rise.

Furthermore, African HBV genotypes and the natural history of African CHB remain poorly

characterized, particularly in children. African CHB is associated with unique genotypes such as

E and A1, although the prevalence of these genotypes outside Australia is poorly described.

Bannister and colleagues found that the HBV genotypes in African children and adults

living in Melbourne largely reflected their country of origin, including genotypes associated with

rapid progression to hepatocellular carcinoma, reduced vaccine efficacy, and recombinant

viruses. Early e-antigen seroconversion was observed, and HBV variants that have previously

been associated with more severe clinical disease progression were seen in around 40% of

children before adulthood. In vitro studies of these genotypes showed differences in the way the

African clones replicated and produced viral proteins, which may have implications for how

these strains produce disease or can be treated. These findings have important ramifications for

patient monitoring and treatment guidelines, particularly in the pediatric setting, in Australia.

Shyamasundaran Kottilil (Institute of Human Virology, USA) reported that chronic

hepatitis C virus (HCV) infections affect approximately 71 million people worldwide and is a

major cause of morbidity, liver cancer, liver transplantation and mortality. Currently, the goal of

HCV therapy is to achieve a “functional cure,” which is defined as a sustained virologic response

(SVR) in which no detectable plasma HCV RNA is detected 12 weeks after therapy. Recently,

oral direct-acting antiviral (DAA) therapy has been shown to be safe, tolerable and highly

effective in achieving SVR without the use of interferon-alpha, which has been associated with
adverse events, long duration, and modest SVR. This is a major milestone in the management of

chronic hepatitis C. Still, most people infected with HCV are not aware of their status, only

twenty percent are in care and less than ten percent are treated. Greater awareness among both

providers and patients is required to optimize the care continuum. Approaches that enable

increased patient screening, effective task-shifting of care, and development of point-of-care

testing strategies for marginalized patients are critical to achieving elimination of hepatitis C

infections (Mathur, et al., 2017).

5.5 Approaches to eliminating persistent viruses, Part 2

HIV and HCV are important global viral pathogens, for which the landscape of

prevention by vaccination and cure through drug treatment is changing substantially.

Glenda Gray (South African Medical Research Council) provided an update on current

HIV vaccine efficacy trials. Although anti-retroviral treatment (ART) is highly successful, it is

expensive, can lead to drug resistance and is difficult to fully implement. Further, half of all HIV

infections are transmitted by subjects within the first 5 months of their infection, often before

they are aware of their infection. It is widely recognized that a HIV vaccine will be an essential

tool in control of the HIV epidemic, especially in regions with high prevalence, such as Southern

Africa. Over the last 20 years, HIV vaccine strategies have evolved from simple protein

approaches or single vectors designed to induce cytotoxic T cells towards heterologous prime-

boost regimens designed to induce broader immunity. The Thai RV 144 trial of a canarypox

vector-gp120 protein prime boost vaccine regiment showed 31.2% efficacy (Rerks-Ngarm et al.,

2009). The 5400 subject HVTN 702 trial is now under way, to see if it can improve upon this
efficacy. At the time of the GVN meeting, 1600 subjects had already been enrolled. A two-stage

follow-up of this trial is planned, to determine if any efficacy is durable.

Gray also reported that planning for a second prime-boost efficacy trial in southern

Africa, the 2600-subject HVTN 705 trial using an adenovirus type 26 vector-gp140 boost

regimen was well advanced. This regimen has showed significant efficacy in monkey trials

(Barouch et al., 2015) and it has been announced subsequent to the GVN meeting that the trial is

going ahead (https://www.nih.gov/news-events/news-releases/nih-partners-launch-hiv-vaccine-

efficacy-study). Separate from the prime-boost vaccine efficacy trials, another efficacy trial of a

passively transferred monoclonal neutralizing antibody (VRC01) is under way in both South

Africa and North America (HVTN 703 and 704 studies). The VRC01 antibody is effective in

preventing infection in monkey models and can reduce HIV levels in infected humans (Gray et

al., 2016; Lynch et al., 2015).

Damian Purcell (The Doherty Institute/University of Melbourne) provided an update on

approaches to an HIV cure. HIV remains latent despite ART, meaning that treatment must

continue for life. Latent HIV can be reactivated with certain drugs that activate virus

transcription, such as histone deacetylase inhibitors, with the hope that the reactivated virus will

then be cleared (the so-called “shock and kill” strategy (Deeks, 2012)). However, recent clinical

trials of these drugs show that their effect is modest and that effects on gene transcription can be

non-specific and prolonged (Sogaard et al., 2015). Newer, more specific, more effective and less

toxic alternatives are needed.

Purcell’s group has developed assays to measure transcription of HIV mediated more

specifically by HIV-1 Tat that lend themselves to high-throughput screens for inhibitors. He

described a novel class of drugs, the amidothiazoles, that appear to specifically activate Tat-
mediated HIV transcription in T-cell lines, with minimal toxicity. Their precise target mode of

action is being studied, as is their ability to reactivate HIV from blood samples from infected

people. This is a promising approach that should ultimately expand the armamentarium of

potential HIV-cure drugs.

Margaret Hellard (Burnet Institute, Melbourne) presented the efforts of her group and

collaborators to eliminate HCV transmission through multipronged efforts to cure large numbers

of patients. The efficacy and simplicity of newer DAAs for hepatitis C provides a window to

reduce transmission by reducing the numbers of viremic subjects. Modelling shows this should

be a highly effective strategy, so long as sufficient numbers of people at risk of transmitting

HCV can be treated. The cost of the newer drugs is coming down in many parts of the world and

Australia’s approach of universal access is facilitating larger scale treatment uptake. Increased

rapid testing for HCV, assessment of liver fibrosis, and treatments administered to transmission

networks in communities are likely to be required to achieve these goals (Pedrana et al., 2017).

5.6 Arboviruses

Arboviruses are some of the most widely distributed viral pathogens that also cause

frequent episodes of epidemic disease. Many factors contribute to the emergence and spread of

these viruses, including globalization, changes in vector competence, climate change, and

spillover events affecting the vectors and the ensuing victims (Gould, et al., 2017). This session

provided research information ranging from mosquito control interventions to epidemiological

understanding to vaccines and virus-host interactions.

Cameron Simmons (University of Melbourne, Australia) described past and present

difficulties with controlling dengue virus (DENV) infections globally, and highlighted strategies
that are currently being employed against mosquitoes to limit the replication and transmission of

many arbovirus infections, including DENV. He detailed current approaches employed by the

World Mosquito Program (WMP; previously known as Eliminate Dengue) to establish the

intracellular bacterium, Wolbachia, in mosquito populations. Wolbachia is a bacterium with the

intriguingly ability to limit virus replication in co-infected cells (Moreira et al., 2009).

Wolbachia-harbouring mosquitoes have been successfully deployed around Cairns, Australia,

and the WMP has initiated similar programs in DENV-endemic areas such as Indonesia, Brazil,

Columbia, Vietnam and India. Simmons underlined some of the challenges of the WMP,

including communication with the local population, the cost of large-scale implementation,

measuring milestones and evidence-based outcomes, and developing methods to measure the

impact of Wolbachia on disease incidence. Still, current results and projections look encouraging

for this approach to limiting arbovirus infections.

Scott Weaver (University of Texas Medical Branch, Galveston, USA), Chair of the

GVN task force on Zika virus (ZIKV), provided a timely update on the dramatic emergence of

ZIKV in South and Central America in 2016, and a historical view on the spread of ZIKV from

Africa to Asia to the South Pacific and now to the Americas (Aliota et al., 2017). Weaver

described the manifestations of the disease in humans (Guillain-Barré syndrome and

microcephaly) and the significant impact infection has on the unborn fetus in infected pregnant

women. One of the most interesting recent observations is the precipitous decline in reported

Zika cases in 2017. The reasons for this are currently unclear though increasing “herd immunity”

may be a factor.

Weaver highlighted recent advances in ZIKV research, emphasising the large volume of

research dedicated over the past few years, and culminating in numerous vaccine candidates
under clinical trials and the development of nonhuman primate models to investigate

pathogenesis. One of the most important considerations from these studies is the potential of

cross-reactive flavivirus antibodies (particularly against either DENV or ZIKV) to enhance

DENV/ZIKV disease in subsequent infection. He identified many of the research gaps that still

remain, particularly in diagnosis, as many of the current diagnostic tests are cross-reactive but

developments with a specific ZIKV anti-NS1 kit look encouraging. (GVN is supporting a ZIKV

serum bank to aid in the development of better diagnostics). Additionally, the proposed herd

immunity generated against ZIKV in the Caribbean and Latin America may hinder the

development of vaccines, as it will be difficult to: 1) assess candidate vaccines in naïve

populations, and 2) market vaccines in the absence of significant new cases (Ferguson et al.,

2016). The principles that underlie the unique pathogenesis and transmission routes of ZIKV still

remain unanswered.

Robert Garry (Tulane Medical School, USA) discussed the development of antibodies

against Lassa fever virus (LASV) and Ebola virus (EBOV), and provided an overview of the

history of these two viruses and efforts to coordinate and establish collaborative networks to

provide outreach and education to affected African communities (Yozwiak et al., 2016). He

described the generation of human monoclonal antibody cocktails targeting the LASV

glycoprotein and the technologies available to produce large quantities of highly specific human

monoclonals, which have proven effective in nonhuman primate models (Mire et al., 2017).

These developments and the construction of bivalent and trivalent vaccine candidates expressing

stabilized LASV and EBOV glycoproteins are encouraging tools against lethal haemorrhagic

fever viruses.
 Marc Lecuit (Biology of Infection Unit, Institut Pasteur and Inserm, France) described

the role of the cellular unfolded protein response (UPR) in the development of ZIKV disease. He

presented evidence that the UPR contributes to neurogenesis and that upregulation of the UPR in

neuronal progenitor cells can impact development, resulting in microcephaly in a mouse model.

He showed compelling data indicating that ZIKV induces the UPR in neuronal progenitor cells;

this was reflected in dysregulated neuronal development and reduced brain mass in ZIKV-

infected fetal mice (Gladwyn-Ng, et al., 2017). Therapeutic interventions alleviating the UPR

reduced the presentation of microcephaly in ZIKV-infected mice, offering the possibility of

therapeutic strategies in this area (Gladwyn-Ng I, et al., 2018).

5.7 Arboviruses and Ebola

John Fazakerley (The Peter Doherty Institute for Infection & Immunity, Australia)

reported on the European Union-funded ‘Integrating Chikungunya Research’ (ICRES)

Programme. ICRES consists of 14 international laboratories working to develop new molecular

and cellular tools for the study of Chikungunya virus; further the understanding of the virus-

vector relationship; develop new diagnostics, antivirals and a vaccine; and advance

understanding of the pathogenesis of the disease and its sequelae. He also presented two studies

of experimental animal models for investigating whether an alphavirus (Semliki Forest virus)

that causes encephalitis can persist in the brain and whether an alphavirus (Chikungunya virus)

that causes arthralgia can persist in joints.

Massimo Palmarini (GVN Center Director at the MRC-University, Glasgow, Scotland)

reported on the innate immune response mediated by type I interferon (IFN), and the resulting

up-regulation of hundreds of IFN-stimulated genes (ISGs or the “interferome”), which provide

an immediate barrier to virus infection. Studies on the type I IFN response have mainly been

carried out at a single-species level, often lacking the comparative power necessary to understand

key evolutionary features of this pathway. Palmarini and colleagues determined common and

unique properties of the interferomes for multiple vertebrate species and developed an open

access webserver to mine the dataset. They reported finding a “core” of 62 ISGs, including genes

not previously associated with IFN, underscoring the ancestral functions associated with the type

IFN response. They showed that gene expansion contributed to the evolution of the IFN system

and that interferomes are shaped by lineage-specific pressures. Furthermore, an analysis of genes

commonly down-regulated by IFN suggests that epigenetic regulation of transcription is a

fundamental aspect of the IFN response.

Joshua Hayward (Burnet Institute, Australia) noted that viral infections of bats typically

produce no signs of clinical disease, raising questions about what innate immune differences

might exist between bats and other mammals. The APOBEC3 gene family encodes antiviral

DNA cytosine deaminases, which are restriction factors with important roles in the suppression

of diverse viruses and genomic parasites. Hayward and colleagues characterized the megabat

(family Pteropodidae) APOBEC3 genes and show that pteropid bats possess the largest and most

diverse array of APOBEC3 genes identified in any mammal reported to date. Several bat

ABOEC3 proteins have been shown to be capable of restricting retroviral infectivity, using HIV-

1 as a model. Hypermutation analysis of the endogenous retroviruses of P. vampyrus support a

role for APOBEC3-mediated restriction of ancient bat retroviruses, and a molecular clock

analysis indicates that the expansion of APOBEC3 genes coincided with the extinction of

pteropid LINE-1 retroelements (Hayward, et al., 2013). These findings reveal the first group of
antiviral restriction factors identified in bats with extensive diversification and divergence

relative to homologues of other mammals.

Didier Fontenille (Institut Pasteur du Cambodge) described the diversity of arbovirus

vectors in Asia. More than 430, 220 and 240 different mosquito species have been identified in

Thailand, Vietnam, and Cambodia, respectively. Little is known about ticks, however, and even

less about sandflies and biting midges. Compared to the diversity of vectors, very few

arboviruses have been identified beyond the “big four”: dengue virus (serotypes 1-4); Japanese

encephalitis virus; chikungunya virus; and more recently, Zika virus. Strategies for vector control

in most Asian countries are few—with rare successes and numerous failures. There appear to be

several reasons for the vector control stalemate, including a paucity of field research, as well as

lack of interest and/or competency in research laboratories.

Fontenille posed a number of questions about the region and the emergence of new

viruses, asking: How can we effectively control vectors? How can we assess the risk of

emergence and outbreak within the frame of environmental, social and climate change? What do

we know about the biology and evolution of mosquitoes (for example, Ae. aegypti vs Ae.

albopictus), and mosquito-virus co-adaptation in Asia? Should Southeast Asia expect the

emergence of Zika virus? Fontenille reviewed these issues and made recommendations for a

more active, holistic research approach involving virologists, zoologists, ecologists, social

scientists and the often-neglected entomologists (Roche, et al., 2017).

5.8 Persistent viruses

Anthony L. Cunningham (University of Sydney, Australia) described the “find me” and

“eat me” signals that attract human dermal dendritic cells (dDCs) to Langerhans cells (LCs)
infected with herpes simplex virus (HSV), and facilitate recognition and uptake of apoptotic LCs

(Botting, et al., 2017). He and his colleagues assessed the expression of chemokines by HSV-

infected LCs and corresponding chemokine receptors on dDC subsets, as well as apoptotic

receptors that may recognize and facilitate their interactions. These studies help to define the

mechanisms of uptake and viral antigen transfer between LCs and dDCs, leading to subsequent

differential presentation to CD4+ and CD8+T-cells, which may define potential dendritic cell

targets for adjuvants in future mucosal or intradermal vaccines.

Zhiwei Chen (AIDS Institute and Department of Microbiology, Hong Kong SAR,

China) reported on “HIV enteropathy” in acute HIV infection, which is characterized by

diarrhea, gastrointestinal inflammation, increased intestinal permeability and malabsorption of

nutrients. Inflammatory mediators such as infiltration and activation of CD8+ T-cells, pro-

inflammatory cytokines and CD4 T-cell depletion likely contribute to these changes in the

intestine following local immune activation. Chen and colleagues have discovered that a subset

of gamma-delta T-cells (∆42PD1+Vδ2) also may contribute to innate immune activation and

mucosal damage during acute HIV infection (Cheung, et al., 2017). These cells may serve as

targets for the investigation of diseases with mucosal inflammation, in addition to initial HIV

infection at the mucosal surface.

Bonnie Howell (Merck, Boston, USA) described the importance of elucidating

mechanisms of HIV-1 persistence and developing innovative strategies for treatment and a

functional cure. A class of small molecules -- histone deacetylase inhibitors (HDACis)—has

been studied as latency-reversing agents, and clinical studies have shown that single and multiple

administration results in induced viral RNA transcription and protein in CD4+ T-cells from

ART-suppressed HIV+ subjects (Wu, et al., 2017). Furthermore, applying novel screening
strategies for latency reversal agents in the presence of a sensitizing agent, such as a HDACi, can

be a useful approach in identifying new mechanisms and alternative therapies for latency

intervention. Notably, the exploration of cure strategies targeting the latent HIV reservoir also

highlights a need for new assays and research tools to quantify viral burden in tissue and various

body fluids. The rare incidence of latently-infected cells, for which robust phenotypic markers

are still needed presents a challenge to identifying these cells and measuring changes in viral

expression, particularly after therapeutic intervention (Wu et al., 2017).

Sarah Palmer (Centre for Virus Research, University of Sydney, Australia) reported that

full-length HIV sequencing techniques revealed the majority of persistent HIV provirus in cells

is genetically defective during antiretroviral therapy (Hiener et al., 2017). However, the

distribution of intact proviruses within memory CD4 + T-cell subsets from participants who

initiated therapy during either acute or chronic infection showed the proportion of intact provirus

was significantly different across cell subsets. Cells expressing the HLA-DR activation marker

and effector memory cells contained the highest proportion of intact HIV genomes. In addition,

clonal expansions of intact proviruses were identified indicating that proliferating cells

contribute to the latent reservoir. The HLA-DR marker identifies cells containing a high

frequency of intact HIV genomes; therefore, assays quantifying the persistent HIV reservoir

should include these cells. Determining the type of cells and cellular mechanisms contributing to

persistent replication-competent HIV is crucial for future efforts aimed at HIV eradication.

5.9 Finale

Ricky Mentha (Baker Heart and Diabetes Research Institute, Australia) reported that

Aboriginal populations residing in remote locations have limited general knowledge of infectious
diseases, modes of transmission, and preventative public health measures. Exposure to an array

of communicable diseases is prevalent, and morbidity and mortality are significant. Effective

partnerships with local Aboriginal stakeholders are critical to improving knowledge of infectious

diseases and developing preventative strategies derived from a well-thought-out research agenda.

Mentha described many pressing needs, including: research grounded in the principles of social

justice and equity; community consultations and partnerships; building capacity with Aboriginal

researchers and community members; and translating findings into policy, practice and health

promotion. There are many complexities to address in conducting communicable disease

research in remote Aboriginal populations, but it can be done in ethical and culturally sensitive

ways that contribute to reducing exposure to poverty-related infectious disease that impact on

morbidity and mortality (Brown et al., 2016).

Kanta Subbarao (WHO Collaborating Centre for Reference and Research on Influenza,

Australia) presented recent data on replication and viral properties governing the airborne

transmission of influenza virus 2009 pandemic A/H1N1 in a ferret transmission model, and

described some of the complex viral and host interactions that influence the transmissibility

phenotype of influenza viruses (Sutton et al., 2017).

Frederick Kristensen (CEPI, Oslo, Norway) described the recently established Coalition

for Epidemic Preparedness Innovations (CEPI). The organization was launched in January, 2017

with an initial investment of more than $500 million provided by the governments of Norway,

Japan and Germany, the Bill & Melinda Gates Foundation and the Wellcome Trust. In addition,

the European Commission agreed to co-fund some CEPI projects with €200 million. Other

funds will be available from Australia, Belgium and Canada. At its launch, CEPI issued a call for
proposals to develop vaccines against three viral agents: MERS-coronavirus, Lassa and Nipah

virus. A new call is planned for developing vaccine platforms.

6. The network in 2017

On October 1, 2017, Christian Bréchot, MD, PhD became the new GVN President

(http://gvn.org/brechot/). He previously served as President of the Institut Pasteur in Paris. Dr.

Bréchot held other leadership positions with the French National Institute of Health and Medical

Research (Inserm), the Institut Mérieux, and the BIOASTER Technology Research Institute. He

previously served as a university professor, hospital practitioner, and head of departments of

hepatology and cell biology. In 1982, Dr. Bréchot received a Doctor of Medicine from Paris

Descartes University (Paris VII) and a PhD in biochemistry from the Paris Descartes

University. Throughout his career, his research has focused on HBV and HCV, particularly

regarding their role in liver cancer and to the molecular mechanisms that drive liver regeneration

and cancer. He is a member of numerous scientific committees and societies and has received a

myriad of prestigious awards. Dr. Bréchot has authored more than 350 articles in medical and

scientific journals.

While there are new changes to the GVN headquarters staff, several other activities have

continued, including the collection of acute and convalescent sera from confirmed Zika patients

to aid in developing new diagnostics. The serum bank is funded by a grant from the Allergan

Foundation, and samples are stored at the University of Texas Medical Branch in Galveston,

Texas. In addition, Shyamasundran Kottilil and colleagues at the Institute of Human Virology in

Baltimore have continued a project with the GVN to expand a training model for health care

providers using DAA treatment for hepatitis C patients in India (Mathur et al., 2017). The
training program is funded by the Gilead Foundation. Similarly, a pilot study to develop an

integrated clinical database to support community-based care of hepatitis B patients in Arunachal

Pradesh, India also is under way, and is funded by the John C. Martin Foundation.

GVN's HTLV-1 task force members published a commentary recommending the current

name for HTLV-1 be changed back to its original name (human T-cell leukemia virus-1), in

keeping with its oncogenicity and pathogenesis (Gallo, et al., 2017). Other GVN investigators

published work on the oncogenicity of HTLV-1 (Tagaya and Gallo, 2017). Members of the GVN

task force on Zika virus also published a major review on what has been learned about Zika in

the first two years of the epidemic in the Americas, and what gaps remain (Aliota MT et al.,

2017).

During 2017, the Network expanded the number of cooperating research centers by

adding the Mérieux Foundation in Lyon, France, and the Rega Institute for Medical Research at

the University of Leuven in Belgium (Figure 1). These two new centers are expected to

strengthen research on vaccines and collaborative activities in developing countries.

7. Plans for 2018

GVN staff will continue to solicit patient serum samples for the Zika serum bank in

Galveston, Texas. Additionally, a project to sequence and conduct phylogenetic analyses of

collected Zika virus isolates is continuing in cooperation with the World Reference Center for

Emerging Viruses and Arboviruses (WRCEVA), which is funded by the National Institute of

Allergy and Infectious Diseases (USA).

The GVN will host the fifth annual Short Course on Medical Virology for young

investigators in the summer of 2018. The Short Course attracts an international class of 15-20
postdoctoral students and fellows for five days of meetings and lectures with experts in medical

virology research and clinical practice. Information about the course and registration is available

online at http://gvn.org.

The 2018 international GVN meeting will be in Annecy, France during November 28-30.

It will be co-hosted by the Research Center for Emerging Infections and Zoonoses at the

University of Veterinary Medicine in Hanover, Germany. The Scientific Organizing Committee

includes: Christian Bréchot, GVN President, USA; Huber Endtz, Scientific Director at the

Fondation Mérieux, France; Robert Gallo, Co-Founder & Scientific Director, GVN; William

Hall, Co-Founder, GVN, University College Dublin, Ireland; Ab Osterhaus, Director of the

Research Center for Emerging Infections and Zoonosis (RIZ), Germany; and Marc Lecuit,

Director of the Biology of Infection Unit at Institut Pasteur, France.

Acknowledgements

We thank the participants who presented their data at the 2017 International GVN Meeting. We

thank The Peter Doherty Institute for Infection and Immunity, and the Australasian Society for

HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) for their outstanding management of

the meeting and related events. Support also was provided by numerous sponsors, including,

Abbvie, the Australian Centre for HIV and Hepatitis Virology Research (ACH 2), the Australian

Centre for Hepatitis Virology, Bioniz, Club Melbourne, CSL Limited, FORT National

Biopharmaceutical Company, Gilead, The Institute of Human Virology/Nigeria, the Melbourne

Convention Exhibition Centre, and ViiV Healthcare.

References

Akkina, R., Ellerbrok, H., Hall, W., Hasagawa, H., Kawaguchi, Y., Kleanthous, H., et al.
2017. Meeting Report: The Eighth International Global Virus Network Meeting.
Antiviral Res. 142:21-29.

Alfano, N., Michaux, J., Morand, S., Aplin, K., Tsangaras, K., Löber, U., et al. 2016.
Endogenous Gibbon Ape Leukemia Virus Identified in a Rodent (Melomys burtoni
subsp.) from Wallacea (Indonesia). J Virol. 90;18:8169-8180.

Aliota, M.T., Bassit, L., Bradrick, S.S., Cox, B., Garcia-Blanco, M.A., Gavegnano, C., et al.
2017. Zika in the Americas, year 2: What have we learned? What gaps remain? A report
from the Global Virus Network. Antiviral Res. 144:223-246.
doi:10.1016/j.antiviral.2017.06.001.

Barouch, D.H., Alter, G., Broge, T., Linde, C., Ackerman, M.E., Brown, E.P., et al. 2015.
Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus
monkeys. Science 349:320-324.

Botting, R.A., Rana, H., Bertram, K.M., Rhodes, J.W., Baharlou, H., Nasr, N., et al. 2017.
Langerhans cells and sexual transmission of HIV and HSV. Rev Med Virol. 27:2. doi:
10.1002/rmv.1923.

Brown, A., Mentha, R., Howard, M., Rowley, K., Reilly, R., Paquet C. 2016. Men, hearts
and minds: developing and piloting culturally specific psychometric tools assessing
psychosocial stress and depression in central Australian Aboriginal men. Soc Psychiatry
Psychiatr Epidemiol. 51:211-23. doi: 10.1007/s00127-015-1100-8.

Cheung, A.K.L., Kwok, H.Y., Huang, Y., Chen, M., Mo, Y., Wu, X. 2017, et al. Gut-homing
∆42PD1+Vδ2 T cells promote innate mucosal damage via TLR4 during acute HIV type 1
infection. Nature Microbiol. 2:1389–1402. doi:10.1038/s41564-017-0006-5

Deeks, S.G., 2012. HIV: Shock and kill. Nature 487:439-440.

ECDC Technical Report. Geographical distribution of areas with a high prevalence of HTLV-
1 infection. 2015.
https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/geographical-
distribution-areas-high-prevalence-HTLV1.pdf. Accessed: January 16, 2018.

Einsiedel, L., Purcell, D., Schinke, S., Haynes, K., Taylor, G.P., Martin, F. 2018. Conference
Report: Highlights from the HTLV-1 symposium at the 2017 Australasian HIV and AIDS
Conference held jointly with the 2017 Australasian Sexual Health Conference, November
2017, Canberra, Australia. J. Virus Erad. 4:48–50. 1514854653JVE_11.pdf. Accessed:
January 27, 2018.
Einsiedel, L., Cassar, O., Spelman, T., Joseph, S., Gessain, A. 2016. Higher HTLV-1c
proviral loads are associated with blood stream infections in an Indigenous Australian
population. J Clin Virol. 78:93-98. doi: 10.1016/j.jcv.2016.03.006.

Einsiedel, L., Fernandes, L., Spelman, T., Steinfort, D., Gotuzzo, E. 2012. Bronchiectasis is
associated with human T-lymphotropic virus 1 infection in an Indigenous Australian
population. Clin Infect Dis. 54;1:43-50. doi: 10.1093/cid/cir766.

Ferguson, N.M., Cucunubá, Z.M., Dorigatti, I., Nedjati-Gilani, G.L., Donnelly, C.A.,
Basáñez, M.G. 2016. Countering the Zika epidemic in Latin America. Science. 353:353-
354.

Gallo, R.C., Willems, L., Tagaya, Y. 2017. Time to Go Back to the Original Name. Frontiers
in Microbiology, 8:1800. http://doi.org/10.3389/fmicb.2017.01800

Ge, X.Y., Li, J.L., Yang, X.L., Chmura, A.A., Zhu, G., Epstein, J.H. 2013. Isolation and
characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature.
503:535-538

Gessain, A., Rua, R., Betsem, E., Turpin, J., Mahieux, R. 2013. HTLV-3/4 and simian foamy
retroviruses in humans: discovery, epidemiology, cross-species transmission and
molecular virology. Virol. 435;1:187-199. doi: 10.1016/j.virol.2012.09.035.

Gladwyn-Ng I, Cordón-Barris L, Alfano C, Creppe C, Couderc T, Morelli G, et al. 2018.

Stress-induced unfolded protein response contributes to Zika virus-associated
microcephaly. Nat Neurosci. 21;1:63-71. doi: 10.1038/s41593-017-0038-4.

Gladwyn-Ng, I., Cordón-Barris, L., Alfano, C., Creppe, C., Couderc, T., Morelli, G., et al.
2017. Stress-induced unfolded protein response contributes to Zika virus-associated
microcephaly. Nat Neurosci. Dec 11. doi: 10.1038/s41593-017-0038-4.

Gould, E., Pettersson, J., Higgs, S., Charrel, R., and Lamballerie, X. 2017. Emerging
arboviruses: Why today? One Health. 4:1-13.

Gray, G.E., Laher, F., Lazarus, E., Ensoli, B., Corey, L., 2016. Approaches to preventative
and therapeutic HIV vaccines. Curr Opin Virol. 17:104-109. doi:
10.1016/j.coviro.2016.02.010.

Hayden, E.C. 2013. Hopes of HIV cure in “Boston patients” dashed. Nature. Dec. 6.
http://www.nature.com/news/hopes-of-hiv-cure-in-boston-patients-dashed-1.14324/
Accessed: January 29, 2018. doi: 10.1038/nature.2013.14324.

Hayward, J.A., Tachedjian, M., Cui, J., Field, H., Holmes, E.C., Wang, L.F. 2013.
Identification of diverse full-length endogenous betaretroviruses in megabats and
microbats. Retrovirol. 27;10:35. doi: 10.1186/1742-4690-10-35.
Hiener, B., Horsburgh, B.A., Eden, J.S., Barton, K., Schlub, T.E., Lee E. 2017. Identification
of Genetically Intact HIV-1 Proviruses in Specific CD4+ T Cells from Effectively
Treated Participants. Cell Rep. 21;3:813-822. doi: 10.1016/j.celrep.2017.09.081.

Hobbs, M., King, A., Salinas, R., Chen, Z., Tsangaras, K., Greenwood, A.D., et al. 2017.
Long-read genome sequence assembly provides insight into ongoing retroviral invasion
of the koala germline. Sci Rep. 7;1:15838. doi: 10.1038/s41598-017-16171-1.

Hu, S., Neff, C.P., Kumar, D.M., Habu, Y., Akkina, S.R., Seki, T. 2017. A humanized mouse
model for HIV-2 infection and efficacy testing of a single-pill triple-drug combination
anti-retroviral therapy. Virol. 501:115-118. doi: 10.1016/j.virol.2016.11.013.

Lynch, R.M., Boritz, E., Coates, E.E., DeZure, A., Madden, P., Costner, P., et al. 2015.
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic
HIV-1 infection. Sci Transl Med. 7;319:319ra206. doi: 10.1126/scitranslmed.aad5752.

Mann, A., 2011. New organization pledges scientific expertise for viral outbreaks. Nat. Med.
17: 394.

Mathur, P., Comstock, E., McSweegan, E., Mercer, N., Kumar, N.S., Kottilil, S. 2017. A
pilot study to expand treatment of chronic hepatitis C in resource-limited settings.
Antiviral Res. 146:184-190. doi: 10.1016/j.antiviral.2017.09.007.

Mire, C.E., Cross, R.W., Geisbert, J.B., Borisevich, V., Agans, K.N., Deer, D.J. 2017.
Human-monoclonal-antibody therapy protects nonhuman primates against advanced
Lassa fever. Nat Med. 23:1146-1149.

Moreira, L.A., Iturbe-Ormaetxe, I., Jeffery, J.A., Lu, G., Pyke, A.T., Hedges, L.M. 2009. A
Wolbachia symbiont in Aedes aegypti limits infection with dengue, Chikungunya, and
Plasmodium. Cell. 139:1268-1278.

Nelson, T.M., Vuillermin, P., Hodge, J., Druce, J., Williams, D.T., Jasrotia, R. 2017. An
outbreak of severe infections among Australian infants caused by a novel recombinant
strain of human parechovirus type 3. Sci Rep 7:44423.

Nix, W.A., Khetsuriani, N., Penaranda, S., Maher, K., Venczel, L., Cselko, Z. 2013.
Diversity of picornaviruses in rural Bolivia. J Gen Virol 94:2017-2028.

Olival, K. J., Hosseini, P. R., Zambrana-Torrelio, C., Ross, N., Bogich, T. L. & Daszak, P.
2017. Host and viral traits predict zoonotic spillover from mammals. Nature 546:646-
650.

Pedrana, A.E., Sacks-Davis, R., Doyle, J.S., Hellard, M.E., 2017. Pathways to the elimination
of hepatitis C: prioritising access for all. Expert Rev Clin Pharmacol 10:1023-1026.
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, et al.
2009. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand.
N Engl J Med 361:2209-2220.

Revill, P., Testoni, B., Locarnini, S., Zoulim, F. 2016. Global strategies are required to cure
and eliminate HBV infection. Nat Rev Gastroenterol Hepatol. 13;4:239-248. doi:
10.1038/nrgastro.2016.7.

Roche B., Gaillard B., Léger L., Pélagie-Moutenda R., Sochacki T., Cazelles B., et al. 2017.
An ecological and digital epidemiology analysis on the role of human behavior on the
2014 Chikungunya outbreak in Martinique. Sci Rep. 7;1:5967. doi: 10.1038/s41598-017-
05957-y.

Satou, Y., Miyazato, P., Ishihara, K., Yaguchi, H., Melamed, A., Miura, M., et al. 2016. The
retrovirus HTLV-1 inserts an ectopic CTCF-binding site into the human genome. Proc
Natl Acad Sci USA. 113;11:3054-3059.

Schmitt, K., Charlins, P., Veselinovic, M., Kinner-Bibeau, L., Hu, S., Curlin, J. 2018. Zika
viral infection and neutralizing human antibody response in a BLT humanized mouse
model. Virol. 5;515:235-242. doi:10.1016/j.virol.2017.12.026.

Schmitt, K., Kumar, D.M., Curlin, J., Mulder, L.R., Stenglein, M., O’Connor, S. 2017.
Modeling the evolution of SIV sooty mangabey progenitor virus towards HIV-2 using
humanized mice. Virol. 510:175-184.

Sogaard, O.S., Graversen, M.E., Leth, S., Olesen, R., Brinkmann, C.R., Nissen, et al. 2015.
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS Pathog
11:e1005142.

Sutton, T.C., Lamirande, E.W., Czako, R., Subbarao, K. 2017. Evaluation of the biological
properties and cross-reactive antibody response to H10 influenza viruses in ferrets. J
Virol. pii: JVI.00895-17. doi: 10.1128/JVI.00895-17.

Tagaya, Y. and Gallo, R.C. The Exceptional Oncogenicity of HTLV-1. 2017. Front
Microbiol. 8:1425. doi: 10.3389/fmicb.2017.01425

Tarlinton, R.E., Meers, J., Young, P.R. 2006. Retroviral invasion of the koala genome.
Nature 442:79-81.

Watashi, K., Urban, S., Li, W., Wakita, T. 2014. NTCP and Beyond: Opening the Door to
Unveil Hepatitis B Virus Entry. Intnl. J. Molc. Sci. 15;2:2892–2905.
http://doi.org/10.3390/ijms15022892

Wu, G., Swanson, M., Talla, A., Graham, D., Strizki, J., Gorman, D., et al. 2017. HDAC
inhibition induces HIV-1 protein and enables immune-based clearance following latency
reversal. JCI Insight. 2:16. pii: 92901. doi: 10.1172/jci.insight.92901.
Yozwiak, N.L., Happi, C.T., Grant, D.S., Schieffelin, J.S., Garry, R.F., Sabeti, P.C. 2016.
Roots, not parachutes: Research collaborations combat outbreaks. Cell. 166:5-8.

Zhang, G., Cowled, C., Shi, Z., Huang, Z., Bishop-Lilly, K. A., Fang, X. 2013. Comparative
analysis of bat genomes provides insight into the evolution of flight and immunity.
Science 339: 456-460.
 IPT
R
C
S
U
N
A
DM
TE
P
E
C
C
A
Figure 1. GVN Centers of Excellence and associated laboratories. Each center has a director
who has made significant contributions to the literature; high productivity in terms of
publications; has served as a regional resource for research, diagnostics and treatment;
programs that interact with other centers in the region, and outreach programs with less
developed countries. Current Center Directors are listed at: http://gvn.org/gvn-centers.
Highlights

 The GVN is an international research network comprised of 40 Centers of Excellence and

6 Affiliates in 24 countries.

 The 2017 Global Virus Network (GVN) Meeting was held in Melbourne, Australia from

September 25-27.

 New data were presented on various aspects of medical virology, therapies, and emerging

viruses in the Australasia region.

 International collaboration is critical to developing new and effective viral vaccines and

therapeutics.

 The 2018 international GVN meeting will be held on November 28-30 in Annecy,

France.